ArticleFrontiers in endocrinology2025
A novel indicator in evaluating endoscopic orbital decompression for thyroid-associated orbitopathy.
Article in Frontiers in endocrinology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To introduce the increase rate of effective orbital volume (IREOV) as a novel indicator for evaluating outcomes of endoscopic orbital decompression in thyroid-associated orbitopathy (TAO). Methods: In this retrospective study, 69 subjects (124 orbits) underwent either medial wall decompression (MWD) or lateral wall decompression (LWD) combined with fat decompression for TAO. Artificial intelligence was used to segment the orbit and calculate IREOV to compare MWD and LWD effectiveness. The impact of postoperative extraocular muscle expansion on IREOV was also assessed, with patients categorized into muscle hypertrophy and fat hyperplasia groups. Results: Using Artificial Intelligence OrbitNet system, the average IREOV was 0.14 ± 0.08. Postoperative IREOV was significantly higher for MWD (0.17 ± 0.07) than for LWD (0.05 ± 0.05) (P<0.001). Medial rectus muscle expansion had the greatest impact on IREOV after MWD, while lateral rectus muscle expansion affected IREOV after LWD. Most importantly, TAO patients with muscle hypertrophy exhibited higher IREOV after MWD compared to those with fat hypertrophy (P<0.001). Proptosis reduction was 3.20 ± 1.37mm for MWD and 3.02 ± 0.68mm for LWD, with no significant difference (P>0.05). Conclusion: Accurate IREOV calculation through artificial intelligence is crucial for evaluating the efficacy of orbital decompression surgery. For TAO patients presenting with fat hyperplasia, LWD should be prioritized to minimize the risk of postoperative extraocular muscle expansion. In cases where MWD is performed on fat hyperplasia patients, rigorous postoperative surveillance for extraocular muscle expansion is essential.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.